Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846196 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
A Phase 1 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 538
- Enrollment target
NCT00846196: Completed Phase 1 study, sponsored by Warner Chilcott.
NCT00846196 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 538 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (797% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846196, a Phase 1 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 538 participants
- Enrollment target
Study Summary
Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2), and exit procedures.
Interventions
- DRUG risedronate DR (Phase III clinical supply)
- DRUG risedronate 35 mg DR (Commercial Tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
What the finished NCT00846196 record still lists
NCT00846196 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (797% higher).
The record links to 0 conditions, and to 2 interventions - of which risedronate DR (Phase III clinical supply) is the first listed.
NCT00846196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00846196 about?
NCT00846196 is a clinical study titled "A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects". Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2), and exit procedures...
What is the current status of trial NCT00846196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 538 participants. The study started on 2009-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00846196?
The interventions under investigation include: risedronate DR (Phase III clinical supply) (DRUG), risedronate 35 mg DR (Commercial Tablet) (DRUG).
Who is sponsoring clinical trial NCT00846196?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00846196's enrollment target sits among peer trials
538 37th of 2000 higher than 1,964 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia